Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Cyclophosphamide. Found 9 abstracts

Chan JK, Java JJ, Fuh K, Monk BJ, Kapp DS, Herzog T, Bell J, Young R. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials. Gynecol Oncol. 2016 Dec;143(3):490-5.   PMCID: PMC5728987
Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015 Apr;121(7):1032-9.   PMCID: PMC5531172
Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. J Clin Oncol. 2015 May;33(13):1482-90.   PMCID: PMC4404425
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 2015 Jan 08;125(2):236-41.   PMCID: PMC4287635
Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2014 Jul;146(1):145-52.
Cioc AM, Vanderwerf SM, Peterson BA, Robu VG, Forster CL, Pambuccian SE. Rituximab-induced changes in hematolymphoid tissues found at autopsy. American journal of clinical pathology. 2008 Oct;130(4):604-12.
Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng Z, Gregson B, Rivers P, Vonderheide RH, Liebowitz DN, Porter DL, June CH. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood. 2003 Sep 15;102(6):2004-13.
Schilder RJ, Brady MF, Spriggs D, Shea T. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2003 Jan;88(1):3-8.
Ozols RF, Markman M, Thigpen JT. ICON3 and chemotherapy for ovarian cancer. Lancet (London, England). 2002 Dec 21;360(9350):2086-7; author reply 2088.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Cyclophosphamide

Antineoplastic Combined Chemotherapy Protocols Cyclophosphamide drug therapy Female Middle Aged administration & dosage therapeutic use Adult Doxorubicin Male Aged Prednisone Paclitaxel Neoplasm Staging Vincristine Kaplan-Meier Estimate Ovarian Neoplasms pathology Carboplatin Monoclonal Antibodies adverse effects Human mortality methods Cisplatin Prognosis Monoclonal Antibodies-Murine-Derived B-Cell Lymphoma Follow-Up Studies Rituximab radiotherapy Prospective Studies 80 and over Aged Time Factors Drug Administration Schedule Chemoradiotherapy Adolescent Proportional Hazards Models Combined Modality Therapy Disease-Free Survival Treatment Outcome Survival Rate analysis Gene Expression doxorubicin Adoptive Transfer Randomized Controlled Trials US Gov't Support-PHS Lymph Nodes and prednisone (R-CHOP) administration & Survival Antineoplastic Agents Cytarabine T-Lymphocytes Intravenous Infusions immunology Parenteral Infusions Ovarian Epithelial Carcinoma Cytoreduction Surgical Procedures Cyclin-Dependent Kinase Inhibitor p27 vincristine Lymphocytosis Melphalan CD34 Antigens metabolism early stage Biomarkers diagnosis Spleen Clear Cell Adenocarcinoma cyclophosphamide Liquid Chromatography Adjuvant Chemotherapy Non-US Gov't Support Ki-67 Antigen Drug Dose-Response Relationship Carmustine Hematopoietic Stem Cell Mobilization Endometrioid Carcinoma Risk Factors Middle Age pharmacology blood Epithelial Cells Disease Progression Vitamin D Deficiency chemistry Large B-Cell Lymphoma-Diffuse surgery Multivariate Analysis Histone Deacetylases Peripheral Blood Stem Cell Transplantation Glandular and Epithelial Neoplasms B-Lymphocytes Remission Induction radiation Breast Neoplasms Hydroxamic Acids Vitamin D Hematopoietic Stem Cells Etoposide Follicular Lymphoma Recurrence Filgrastim Consolidation Chemotherapy transplantation Carcinoma Immunohistochemistry consolidation Autopsy Child Early stage ovarian cancer Hematopoietic Stem Cell Transplantation Tumor Biomarkers dosage Non-Hodgkin Lymphoma Cystic Neoplasms-Mucinous-and Serous Young Adult Pilot Projects Cyclin-Dependent Kinase Inhibitor p21 Tandem Mass Spectrometry therapy genetics analogs & derivatives drug effects
Last updated on Saturday, July 11, 2020